Human immunodeficiency virus-1 infection in neonates: correlation of plasma and cellular viremia and clinical outcome. French Pediatric Cohort Study Group

Acta Paediatr Suppl. 1997 Jun:421:17-21. doi: 10.1111/j.1651-2227.1997.tb18314.x.

Abstract

Among human immunodeficiency virus-1 (HIV-1) vertically infected children, two patterns of disease progression have been observed: about 25% develop a severe immunodeficiency within the first 2 years of life; the rest experience a slower progression, like adults. We have assessed infectious viral burden in infected neonates through the French National Prospective Study. Plasma and cell-associated viremia were assayed by endpoint-dilution cultures in samples from 46 infants followed prospectively from birth. Plasma and cell-associated viral burden were found to be significantly higher in rapid progressing infants than in non-progressing infants in the first months of life: before the age of 2 months, between 2 and 4 months of age and by the age of 6 months. Moreover, among the non-progressing children, the infectious viral burden before the age of 4 months was predictive of the viral burden measured after the age of 12 months. In conclusion, this work demonstrates that infectious viral load is a reliable predictive marker for rapid progression to AIDS in infants and could be useful for initiating antiretroviral therapy.

MeSH terms

  • Age Factors
  • Disease Progression
  • HIV Infections / blood
  • HIV Infections / congenital*
  • HIV Infections / physiopathology
  • HIV-1*
  • Humans
  • Infant
  • Infant, Newborn
  • Predictive Value of Tests
  • Prospective Studies
  • Viral Load*
  • Viremia